S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NASDAQ:LGVN

Longeveron News Headlines

$8.00
+0.78 (+10.80%)
(As of 05/13/2022 06:55 PM ET)
Add
Compare
Today's Range
$7.20
$8.35
50-Day Range
$5.06
$15.61
52-Week Range
$2.84
$45.00
Volume
869,300 shs
Average Volume
3.92 million shs
Market Capitalization
$167.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-2.05
Get Longeveron News Delivered to You Automatically

Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Longeveron Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

LGVN
News Sentiment

0.40

0.48

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

LGVN Articles
This Week

12

6

LGVN Articles
Average Week



Longeveron (NASDAQ:LGVN) News Headlines Today

SourceHeadline
marketbeat.com logoShort Interest in Longeveron Inc. (NASDAQ:LGVN) Declines By 52.2%
marketbeat.com - May 13 at 11:34 AM
benzinga.com logoRecap: Longeveron Q1 Earnings - Benzinga - Benzinga
benzinga.com - May 13 at 4:57 PM
globenewswire.com logoLongeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results - GlobeNewswire
globenewswire.com - May 13 at 4:57 PM
finance.yahoo.com logoLGVN: CEO Leaving but Progress Continues
finance.yahoo.com - May 13 at 4:57 PM
finance.yahoo.com logoLongeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
finance.yahoo.com - May 13 at 4:57 PM
benzinga.com logoLongeveron's Earnings: A Preview - Benzinga - Benzinga
benzinga.com - May 12 at 12:01 PM
MarketBeat logoLongeveron (LGVN) Scheduled to Post Quarterly Earnings on Friday
americanbankingnews.com - May 11 at 3:56 AM
globenewswire.com logoLongeveron Announces CEO Transition - GlobeNewswire
globenewswire.com - May 9 at 6:33 PM
finance.yahoo.com logoLongeveron Announces CEO Transition
finance.yahoo.com - May 9 at 6:33 PM
finance.yahoo.com logoLongeveron to Announce First Quarter 2022 Financial Results on May 13, 2022
finance.yahoo.com - May 9 at 1:33 PM
seekingalpha.com logoLongeveron: Small-Cap Biotech Targeting Large Alzheimer's Market - Seeking Alpha
seekingalpha.com - May 6 at 2:49 PM
finance.yahoo.com logoInvestors in Longeveron (NASDAQ:LGVN) have made a favorable return of 78% over the past year
finance.yahoo.com - April 28 at 2:20 PM
msn.com logoAnalyzing Longeveron Inc. - common stock's Short Interest
msn.com - April 21 at 8:09 AM
bloomberg.com logoAnti-Aging And Biotech (Radio) - Bloomberg
bloomberg.com - April 20 at 3:40 PM
benzinga.com logoLongeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans - Benzinga
benzinga.com - April 14 at 10:49 AM
globenewswire.com logoLongeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer's Symposium; International Frailty and Sarcopenia Research Conference - GlobeNewswire
globenewswire.com - April 14 at 10:49 AM
finance.yahoo.com logoLongeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference
finance.yahoo.com - April 14 at 10:49 AM
globenewswire.com logoLongeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer's Trial - GlobeNewswire
globenewswire.com - April 13 at 8:40 AM
finance.yahoo.com logoLongeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial
finance.yahoo.com - April 13 at 8:40 AM
nasdaq.com logoRecession Fears are Creating a Golden Opportunity for Biotech Stocks - Nasdaq
nasdaq.com - April 10 at 5:04 PM
investorplace.com logoRecession Fears are Creating a Golden Opportunity for Biotech Stocks - InvestorPlace
investorplace.com - April 8 at 5:45 PM
benzinga.com logo5 Stocks To Watch For April 6, 2022 - Benzinga - Benzinga
benzinga.com - April 6 at 4:02 AM
globenewswire.com logoLongeveron Expands Executive Leadership Team; Appoints K. Chris Min, MD, Ph.D. as Chief Medical Officer - GlobeNewswire
globenewswire.com - April 5 at 9:46 AM
finance.yahoo.com logoLongeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer
finance.yahoo.com - April 5 at 9:46 AM
seekingalpha.com logoProtalix, Biophytis top healthcare gainers; while Curis, Longeveron lead losers' pack - Seeking Alpha
seekingalpha.com - April 4 at 12:29 PM
benzinga.com logoLongeveron Shares Quiet As Traders Circulate Zack's Small Cap Research Note Showing $20 Valuation Target - Benzinga
benzinga.com - April 1 at 12:17 PM
finance.yahoo.com logoLGVN: LGVN Publishes Positive Alzheimer’s Results
finance.yahoo.com - April 1 at 12:17 PM
marketwatch.com logoLongeveron Shares Surge 65% After Lomecel-B Trial Meets Primary Endpoint - MarketWatch
marketwatch.com - April 1 at 2:16 AM
finance.yahoo.com logoOil prices: Higher crude the 'No. 1' risk to recent market rally, says strategist - Yahoo Finance
finance.yahoo.com - March 31 at 9:16 PM
streetinsider.com logoR&D Efforts for Alzheimer's Therapies on the Rise with over 120 Drugs in Development - StreetInsider.com
streetinsider.com - March 31 at 9:16 PM
investing.com logoMidday Stock Movers: Longeveron Surges, Dell, UiPath, Expensify Plunge By Investing.com - Investing.com
investing.com - March 31 at 4:15 PM
benzinga.com logoAnalyzing Longeveron Inc. - common stock's Short Interest - Benzinga - Benzinga
benzinga.com - March 31 at 4:15 PM
marketwatch.com logoLongeveron Shares Rise 39% After Results for Alzheimer's Treatment Trial - MarketWatch
marketwatch.com - March 31 at 4:15 PM
globenewswire.com logoLongeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer's Disease in Alzheimer's & Dementia®: The Journal of the Alzheimer's Association - GlobeNewswire
globenewswire.com - March 31 at 9:56 AM
finance.yahoo.com logoLongeveron Publishes Peer Reviewed Study of Phase 1 Trial Results of Lomecel-B for Alzheimer’s Disease in Alzheimer’s & Dementia®: The Journal of the Alzheimer’s Association
finance.yahoo.com - March 31 at 9:56 AM
benzinga.com logoHealthspan, Not Lifespan Should Be the Focus of Anti-Aging Research, Says Longeveron - Benzinga - Benzinga
benzinga.com - March 30 at 9:27 AM
benzinga.com logoMaxim Group Initiates Coverage On Longeveron with Buy Rating, Announces Price Target of $14 - Benzinga - Benzinga
benzinga.com - March 24 at 5:58 PM
benzinga.com logoBenzinga's Top Ratings Upgrades, Downgrades For March 24, 2022 - Benzinga - Benzinga
benzinga.com - March 24 at 10:22 AM
benzinga.com logoLongeveron Shares Trading Higher Premarket; Seeing Maxim Group Starts With Buy Rating And Target Price Of - Benzinga
benzinga.com - March 24 at 10:22 AM
globenewswire.com logoLongeveron Presents at Second Euro-Geroscience Conference - GlobeNewswire
globenewswire.com - March 24 at 10:22 AM
finance.yahoo.com logoLongeveron Presents at Second Euro-Geroscience Conference
finance.yahoo.com - March 24 at 10:22 AM
nasdaq.com logoMy No. 2 Stock Pick For 2022 Rises 100%… - Nasdaq
nasdaq.com - March 17 at 3:35 PM
finance.yahoo.com logoLongeveron to Present at Oppenheimer 32nd Annual Healthcare Conference
finance.yahoo.com - March 15 at 9:35 AM
benzinga.com logoLongeveron Announces Fourth Quarter And Full Year 2021 Financial Results And Operational Progress
benzinga.com - March 14 at 1:33 PM
finance.yahoo.com logoLongeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress - Yahoo Finance
finance.yahoo.com - March 11 at 11:37 PM
seekingalpha.com logoClearside, Cellectis top healthcare gainers; Orphazyme, Aesthetic lead losers' pack - Seeking Alpha
seekingalpha.com - March 11 at 6:36 PM
finance.yahoo.com logoLGVN: Longeveron Continues to Make Progress
finance.yahoo.com - March 11 at 1:35 PM
globenewswire.com logoLongeveron Announces Fourth Quarter and Full Year 2021 - GlobeNewswire
globenewswire.com - March 11 at 8:35 AM
investorplace.com logoAmazon Stock Split 2022: Is the AMZN Split Good or Bad? 4 Analysts Weigh In. - InvestorPlace
investorplace.com - March 10 at 3:40 PM
investorplace.com logoWhy Is Longeveron (LGVN) Stock Up Today?
investorplace.com - March 10 at 12:04 PM
seekingalpha.com logoKala, Natera top healthcare gainers; Sunshine Biopharma, Myomo lead losers' pack - Seeking Alpha
seekingalpha.com - March 10 at 10:39 AM
Get Longeveron News Delivered to You Automatically

Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.